Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Advaxis CSO Invited to Speak at Immune Profiling World Congress

Posted on: 06 Oct 16

PRINCETON, N.J., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Robert Petit, Ph.D., executive vice president and chief scientific officer of Advaxis, was invited to speak at the Immune Profiling World Congress in Barcelona on October 10 – 12, 2016.  

Dr. Petit will deliver a lecture entitled, “Realizing the promise of neoantigens: Using live attenuated bacteria to generate personalized cancer immunotherapies,” during the immuno-oncology approaches portion of the agenda. Dr. Petit will detail Advaxis’ core Lm Technology™ and the promise of neoantigens as he discusses stimulating the innate and adaptive arms of the immune system and the potential reduction in tumor defense mechanisms. In addition, he will share data of patients with cervical cancer and discuss applications to other cancers, as well as the potential for combination of listeria vectors with checkpoint inhibitors and co-stimulatory agonists.

Dr. Petit’s talk is scheduled for Wednesday, October 12, at 9:40 a.m. local time at Fairmont Rey Juan Carlos, Barcelona.

The Immune Profiling World Congress brings together experts to discuss profiling of the immune system, how using high throughput technologies can aid therapeutic design and treatment strategies during keynotes, presentations and roundtables. More than 400 researchers from academia and industry are expected to attend. The event is co-located with Europe's most successful vaccine event, World Vaccine Congress Europe, and the World Veterinary Vaccine Congress.

Dr. Petit has more than 20 years of experience in all medical and scientific aspects of pharmaceutical development, including having led programs in discovery, translational development and intellectual property development, and he has designed and conducted U.S. and international clinical evaluation programs from Phase 1 to 4. Prior to joining Advaxis, he was U.S. medical strategy lead, director of medical strategy for new oncology products, and director of global clinical research at Bristol-Myers Squibb.

About Advaxis, Inc.

Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology immunotherapy, AXAL, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three potential indications: Phase 3 in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase 2 in anal cancer. The FDA has granted AXAL orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for HRLACC patients and a Special Protocol Assessment for the Phase 3 AIM2CERV trial in HRLACC patients. AXAL has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the European Medicines Agency's Committee for Advanced Therapies. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development.  In addition, Advaxis and Amgen are developing ADXS-NEO, a preclinical investigational cancer immunotherapy treatment designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans to enter the clinic in 2017.

For additional information on Advaxis, visit and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.

Advaxis Forward-Looking Statement

This press release contains forward-looking statements, including, but not limited to: statements regarding the completion and timing of the offering of shares. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2015, which is available at, as well as the risks identified or incorporated by reference in the registration statement and the prospectus supplement relating to the offering. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.



Advaxis, Inc.
Greg Mayes, Executive Vice President and CBO

Media Contact:

JPA Health Communications
David Connolly


Last updated on: 07/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.